List of Excipients in Branded Drug AEMCOLO

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RedHill Biopharma Ltd	AEMCOLO	rifamycin	57841-1200	AMMONIO METHACRYLATE COPOLYMER TYPE B	2028-11-16
RedHill Biopharma Ltd	AEMCOLO	rifamycin	57841-1200	ASCORBIC ACID	2028-11-16
RedHill Biopharma Ltd	AEMCOLO	rifamycin	57841-1200	FERRIC OXIDE YELLOW	2028-11-16
RedHill Biopharma Ltd	AEMCOLO	rifamycin	57841-1200	GLYCERYL DISTEARATE	2028-11-16

Aemcolo Excipient Strategy and Commercial Opportunities

Last updated: October 10, 2026

Aemcolo is a differentiated oral rifamycin product whose commercial value depends on localized intestinal delivery, delayed release, and manufacturing control rather than on the active ingredient alone. The product contains rifamycin sodium, equivalent to 194 mg of rifamycin SV, in a delayed-release tablet approved by the FDA for travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults and pediatric patients weighing at least 12 years of age and 40 kg.[1]

Its excipient platform creates opportunities in enteric coating, dissolution control, generic development, contract manufacturing, and alternative rifamycin delivery systems. The principal commercial constraint is that a substitute product must reproduce the product's release profile and therapeutic performance while avoiding applicable formulation and method-of-use patents.

What is Aemcolo and how does its formulation work?

Aemcolo is an oral delayed-release tablet designed to release rifamycin in the colon. The formulation limits systemic exposure and concentrates the antibiotic at the site of intestinal infection.[1]

Aemcolo product profile

Attribute	Aemcolo
Active ingredient	Rifamycin sodium
Active moiety	Rifamycin SV
Strength	194 mg rifamycin SV equivalent per tablet
Dosage form	Delayed-release tablet
FDA approval	November 2018
Approved indication	Travelers' diarrhea caused by noninvasive E. coli
Approved population	Adults and pediatric patients at least 12 years old and weighing at least 40 kg
Administration	Two tablets twice daily for three days
Key delivery objective	Colonic release with limited systemic absorption
Original developer	Cosmo Pharmaceuticals
U.S. commercial rights history	Rights transferred to RedHill Biopharma in 2019

The prescribing information states that rifamycin exposure in plasma is low relative to intestinal exposure. The product is therefore dependent on tablet architecture, coating performance, gastrointestinal transit, and dissolution behavior.[1]

What excipients are used in Aemcolo tablets?

The Aemcolo prescribing information identifies a conventional tablet core combined with functional coating excipients. The listed inactive ingredients include microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, hypromellose, methacrylic acid copolymer, talc, titanium dioxide, and yellow ferric oxide.[1]

Functional role of the excipients

Excipient	Likely formulation function
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant for tablet-core breakup after coat dissolution
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming polymer and coating support
Methacrylic acid copolymer	Enteric or pH-dependent release polymer
Talc	Anti-tacking and coating-process aid
Titanium dioxide	Opacifier and colorant
Yellow ferric oxide	Tablet colorant

The commercial importance of these materials differs. Microcrystalline cellulose and magnesium stearate are widely available and generally offer limited differentiation. The release-controlling polymer system is more important because it determines resistance to gastric conditions, onset of release, coating integrity, and dissolution in intestinal fluid.

The public prescribing information does not disclose quantitative excipient levels or the complete manufacturing process. That limits direct replication based solely on the label and increases the value of reverse engineering, comparative dissolution testing, and process development.

Which excipients create the greatest commercial opportunity?

The strongest opportunities are in functional excipients that control site-specific release.

Enteric polymer systems

Methacrylic acid copolymers can be selected and engineered for different dissolution thresholds. Variations in polymer type, molecular weight, ratio of acidic to neutral monomers, plasticizer system, coating weight, and curing conditions can shift the release profile.

Potential suppliers and development partners include manufacturers of methacrylic acid copolymers, hypromellose-based coating systems, and aqueous film-coating dispersions. A supplier that can provide reproducible pH-triggered release and low batch variability may capture value even where the underlying excipient is not novel.

Coating-process technologies

Aemcolo-type products require more than a list of excipients. Commercial performance depends on:

• Coating uniformity across tablets
• Resistance to gastric fluid
• Adhesion of the coating to the tablet core
• Prevention of cracking during packaging and transport
• Reproducible dissolution after intestinal pH transition
• Control of coating weight gain
• Stability under temperature and humidity stress

Equipment suppliers and contract development and manufacturing organizations can differentiate through coating process control, in-line weight monitoring, fluid-bed or pan-coating optimization, and dissolution analytics.

Alternative coating platforms

A generic or follow-on product could investigate:

• Methacrylic acid copolymer systems with different pH thresholds
• Cellulose acetate phthalate or related enteric polymers
• Multilayer coating systems
• Compression-coated tablets
• Multiparticulate pellets filled into capsules
• Enteric-coated mini-tablets
• Colon-targeted matrix systems

Each alternative creates a regulatory and bioequivalence question. A substantially different dosage form may require more extensive comparative performance data than a conventional delayed-release tablet.

How strong is the excipient strategy for Aemcolo?

The excipient strategy is commercially strong because it supports a clear product attribute: localized intestinal delivery with low systemic exposure. The formulation is less defensible as a simple composition because most listed excipients are standard pharmaceutical materials.

Strategic strength by component

Component	Strategic strength	Commercial implication
Rifamycin SV active ingredient	Moderate	Known antibiotic with established pharmacology
Delayed-release design	High	Central to product performance and indication
Enteric polymer system	High	Can create formulation and process barriers
Conventional tablet excipients	Low to moderate	Readily replaceable in many generic programs
Coating process	High	May be difficult to reproduce from public information
Site-specific intestinal delivery	High	Supports clinical differentiation
Color and appearance	Low	Limited competitive value
Manufacturing know-how	Moderate to high	Can affect dissolution, stability, and scale-up

The strongest barrier is not the identity of any single excipient. It is the combination of polymer selection, coating architecture, process parameters, dissolution specifications, and stability controls.

What patents protect Aemcolo?

Aemcolo protection may involve formulation patents, dosage-form patents, manufacturing claims, and method-of-use claims. The relevant rights should be assessed through the FDA Orange Book, USPTO records, and litigation databases.[2][3]

Patent categories relevant to Aemcolo

Formulation patents

These may cover:

• Rifamycin SV in a delayed-release oral dosage form
• A tablet with a defined enteric coating
• A pH-dependent release system
• Low-systemic-exposure rifamycin delivery
• Specific polymer combinations or coating structures

Method-of-use patents

Potential claims may address treatment of travelers' diarrhea with a rifamycin formulation, dosing frequency, treatment duration, or patient population.

Manufacturing patents

These may cover coating methods, curing conditions, tablet construction, or process parameters that produce a defined dissolution profile.

A generic applicant would need to assess listed patents under the Hatch-Waxman framework and determine whether to file a Paragraph III certification, Paragraph IV certification, or a statement that a patent is not applicable. The commercial significance of each patent depends on its claims, expiration date, regulatory listing status, and litigation history.

What is the FDA regulatory status and Orange Book position of Aemcolo?

Aemcolo was approved under a new drug application in 2018. The FDA labeling identifies the delayed-release dosage form and the clinical use limitations.[1] The Orange Book is the controlling public source for listed patents, exclusivity, therapeutic equivalence evaluations, and approved product information.[2]

Regulatory issues for a generic Aemcolo product

A generic applicant would likely need to demonstrate:

1. Pharmaceutical equivalence to the reference product.
2. Bioequivalence under the applicable FDA pathway.
3. Comparable delayed-release behavior.
4. Appropriate dissolution across gastric and intestinal pH conditions.
5. Manufacturing controls for the enteric coating.
6. Stability through the proposed shelf life.
7. Compliance with the reference product's dosage-form and strength requirements.

Because Aemcolo is designed to minimize systemic exposure, conventional plasma pharmacokinetic testing may not fully describe local intestinal performance. FDA may consider dissolution, pharmacokinetic, clinical, or other comparative data depending on the product and regulatory pathway. The relevant product-specific guidance and FDA correspondence would be important in determining the likely development burden.[4]

When does Aemcolo lose exclusivity?

Aemcolo's commercial exclusivity is determined by the interaction of FDA statutory exclusivity and patent rights. New chemical entity exclusivity, orphan exclusivity, pediatric exclusivity, listed patents, and any patent-term adjustment can produce different end dates.

The product's active ingredient, rifamycin SV, is not a new molecular entity in the broad pharmacological sense. The commercial protection therefore depends heavily on formulation, use, regulatory exclusivity, and patent status rather than on long-term molecule-level exclusivity.

A precise market-entry date should be based on the current Orange Book entry and patent records. Patent expiration alone does not establish launch freedom if other listed patents, regulatory exclusivities, litigation outcomes, or settlement restrictions remain relevant.[2][3]

Which companies are challenging Aemcolo?

Publicly disclosed competition is more likely to arise from generic manufacturers, alternative rifamycin products, and competing travelers' diarrhea therapies than from biosimilar developers.

Competitive categories

Competitor category	Relevance to Aemcolo
Generic rifamycin delayed-release tablets	Direct substitution risk
Rifaximin products	Closest branded and therapeutic comparator
Azithromycin	Alternative travelers' diarrhea treatment
Fluoroquinolones	Older alternative, limited by resistance and safety considerations
Non-antibiotic therapy	Relevant in selected mild or self-limited cases
Alternative colon-targeted antibiotics	Potential future formulation competition

Rifaximin is the closest commercial comparator because it is also a minimally absorbed rifamycin-class antibiotic used in gastrointestinal indications. Aemcolo differs in active ingredient, approved indication, dosage form, and release technology.

How does Aemcolo compare with rifaximin?

Issue	Aemcolo	Rifaximin products
Active ingredient	Rifamycin SV	Rifaximin
Delivery objective	Delayed colonic release	Product-specific intestinal delivery
Major U.S. indications	Travelers' diarrhea	Travelers' diarrhea, hepatic encephalopathy, IBS-D, depending on product
Dose in travelers' diarrhea	194 mg, two tablets twice daily for three days	Product-specific
Systemic exposure	Low	Low
Patent strategy	Formulation and use protection	Broad indication, formulation, and use protection
Commercial breadth	Narrower	Broader
Generic risk	Depends on listed patents and reference-product requirements	Varies by indication and patent estate

Rifaximin has a larger commercial footprint because of multiple U.S. indications. Aemcolo's narrower indication makes its revenue more sensitive to travel patterns, prescriber awareness, reimbursement, and availability through travel-medicine channels.

What formulation opportunities exist beyond Aemcolo?

Aemcolo's platform can support line extensions if the regulatory and patent position permits.

Potential product extensions

• Lower-strength tablets for weight-based or pediatric dosing
• Capsule-based delayed-release multiparticulates
• Single-dose or once-daily regimens
• Combination products for travelers' diarrhea
• Products targeting inflammatory bowel conditions
• Colon-delivery systems for other poorly absorbed antibiotics
• Stable formulations for tropical and emerging markets
• Ready-to-dispense travel packs

The most commercially attractive extension would reduce pill burden while maintaining local intestinal exposure. A once-daily product could improve adherence, but it would require supporting clinical and formulation data.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are coating reproducibility and release-profile control. A product can contain the same excipients and still fail equivalence if the coating thickness, polymer distribution, tablet porosity, curing conditions, or dissolution behavior differs materially.

The main intellectual-property barriers are likely to include formulation claims and method-of-use claims. A competitor could attempt a design-around using a different enteric polymer, a multiparticulate system, or a different tablet architecture. That approach would not eliminate regulatory risk. The alternative product would still need to demonstrate equivalent performance and could face infringement allegations if broad functional claims cover the resulting release profile.

What licensing opportunities exist for Aemcolo-related technology?

Licensing opportunities can arise at four levels:

1. Rifamycin formulation rights.
2. Enteric polymer and coating technology.
3. Regional commercialization rights.
4. Contract development and manufacturing arrangements.

Cosmo Pharmaceuticals originally developed Aemcolo and transferred U.S. commercial rights to RedHill Biopharma. That history indicates that regional rights, commercialization funding, and manufacturing access are material to the product's business model.

Potential counterparties include specialty pharmaceutical companies with travel-medicine portfolios, gastrointestinal-focused companies, generic manufacturers, and excipient suppliers seeking a platform application for colon-targeted delivery.

What revenue exposure and generic launch risks exist?

Aemcolo has a narrower revenue base than rifaximin products because its principal U.S. indication is travelers' diarrhea. Revenue is exposed to international travel volume, seasonal demand, travel-clinic prescribing, payer coverage, and product availability.

Generic launch scenarios

Scenario	Commercial effect
No approved generic before patent expiry	Continued branded pricing, subject to demand
First Paragraph IV generic launch	Potential 180-day exclusivity and rapid price erosion
Multiple generic entrants	Faster price compression
Authorized generic	Lower-price competition controlled by the brand owner or licensee
Reformulated competitor	Possible competition without direct substitution
Manufacturing interruption	Supply-driven loss of share and channel disruption

For an excipient supplier, the best opportunity may not depend on a direct Aemcolo generic. The same enteric coating and colon-delivery capabilities can support other gastrointestinal products, where market size and indication breadth are greater.

Key Takeaways

• Aemcolo is a rifamycin SV delayed-release tablet designed for local intestinal delivery.
• The commercially important excipient is the enteric release system, particularly the methacrylic acid copolymer-based coating.
• Standard tablet excipients offer limited differentiation, while coating architecture and process controls create practical barriers.
• Generic development will depend on pharmaceutical equivalence, dissolution performance, stability, and applicable patent certifications.
• Rifaximin is the closest commercial comparator, but its broader indication base gives it greater revenue scale.
• The strongest commercial opportunities are in enteric polymers, coating process technology, contract manufacturing, regional licensing, and follow-on colon-delivery products.
• Aemcolo's market exposure is concentrated in travelers' diarrhea and is sensitive to travel volume, reimbursement, and generic-entry timing.
• Current FDA and USPTO records should govern any final assessment of Orange Book listings, patent expiration, Paragraph IV activity, and launch freedom.

FAQs

Is Aemcolo an enteric-coated tablet?

Yes. Aemcolo is a delayed-release tablet that uses a pH-dependent coating system to limit release in the stomach and promote intestinal delivery.[1]

Which excipient is most important for Aemcolo's performance?

The methacrylic acid copolymer is the most commercially significant listed excipient because it contributes to pH-dependent release. Coating weight, curing, and process conditions are also important.

Can a generic manufacturer replace Aemcolo's excipients?

A generic manufacturer may use different excipients if the product meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, safety, and performance. A formulation change may increase development and regulatory risk.

Is Aemcolo interchangeable with rifaximin?

No. Aemcolo contains rifamycin SV, while rifaximin products contain rifaximin. They are different active ingredients and are not automatically interchangeable.

Does Aemcolo have biosimilar competition?

No. Biosimilar competition is not the relevant pathway because Aemcolo is a small-molecule oral tablet, not a biologic. Competition would generally arise through generic, reformulated, or therapeutically substitutable products.

References

1. U.S. Food and Drug Administration. (2018). Aemcolo (rifamycin) delayed-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. United States Patent and Trademark Office. (n.d.). Patent Center.
4. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.